Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (SEROQUEL®) Compared With Placebo in the Treatment of Generalized Anxiety Disorder
The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Research Site
Springdale, Arizona, United States
Research Site
Little Rock, Arkansas, United States
Research Site
Encino, California, United States
Research Site
Newport Beach, California, United States
Research Site
Oceanside, California, United States
Research Site
Redlands, California, United States
Research Site
Santa Ana, California, United States
Research Site
Denver, Colorado, United States
Research Site
Norwich, Connecticut, United States
Research Site
Washington D.C., District of Columbia, United States
Start Date
April 1, 2006
Completion Date
August 1, 2007
Last Updated
March 25, 2009
876
ESTIMATED participants
Quetiapine fumarate
DRUG
Lead Sponsor
AstraZeneca
NCT07429578
NCT06661460
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions